AR046601A1 - Uso de derivados 1- aminociclohexano para modificar la deposicion de peptidos ab fibrosos en amiloidopatias - Google Patents

Uso de derivados 1- aminociclohexano para modificar la deposicion de peptidos ab fibrosos en amiloidopatias

Info

Publication number
AR046601A1
AR046601A1 ARP040103865A ARP040103865A AR046601A1 AR 046601 A1 AR046601 A1 AR 046601A1 AR P040103865 A ARP040103865 A AR P040103865A AR P040103865 A ARP040103865 A AR P040103865A AR 046601 A1 AR046601 A1 AR 046601A1
Authority
AR
Argentina
Prior art keywords
aminocyclohexane derivative
amyloidopathy
peptides
aminocyclohexane
beta
Prior art date
Application number
ARP040103865A
Other languages
English (en)
Original Assignee
Merz Pharma Gmbh & Co Kgaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34885905&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR046601(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merz Pharma Gmbh & Co Kgaa filed Critical Merz Pharma Gmbh & Co Kgaa
Publication of AR046601A1 publication Critical patent/AR046601A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Uso de antagonistas del receptor de NMDA, tal como derivados 1-aminociclohexano como ejemplo: memantina, neramexano, entre otros para modificar la deposición de peptidos A beta potencialmente toxico y fibrosos en amiloidopatias. Específicamente, la invención se relaciona con la capacidad de la memantina para intervenir en el procesamiento de (APP) proteína precursora beta-amiloide y disminuir los niveles de peptidos A beta fibrosos. Reivindicación 1: Un método para disminuir el nivel de al menos un pcptido amiloide producido por una célula de mamífero, caracterizado porque dicho método comprende la administración a dicha célula de un derivado 1-aminociclohexano. Reivindicación 18: Un método para tratar, prevenir, detener, demorar el inicio y/o reducir el riesgo de desarrollar una amiloidopatia en un mamífero, caracterizado porque comprende la administración a dicho mamífero de una composición que comprende un derivado 1-aminociclohexano en cantidades eficaces para disminuir la cantidad de peptidos A beta en el cerebro, liquido cerebroespinal o plasma mamífero. Reivindicación 35: El método de la cláusula 18, caracterizado porque el derivado 1-aminociclohexano es administrado de forma simultánea o consecutiva con otro derivado 1-aminociclohexano, un inhibidor de acetilcolinesterasa (ACEI), un modificador de la secretasa o una combinación de los mismos. Reivindicación 37: Un método para controlar el tratamiento en un paciente que padece una amiloidopatia o que tiene riesgo de desarrollar una amiloidopatia, caracterizado porque comprende: proveer a dicho paciente una cantidad de un derivado 1-aminociclohexano, donde dicha cantidad disminuye los niveles de Abeta, y detectar un nivel de Abeta en el fluido corporal de dicho paciente que permita determinar la eficacia de dicho derivado 1-aminociclohexano. Reivindicación 44: El uso de un derivado 1-aminociclohexano, caracterizado porque es para la elaboración de un medicamento destinado a disminuir los niveles de Abeta en un fluido corporal o en el cerebro de un paciente.
ARP040103865A 2003-10-22 2004-10-22 Uso de derivados 1- aminociclohexano para modificar la deposicion de peptidos ab fibrosos en amiloidopatias AR046601A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51370003P 2003-10-22 2003-10-22

Publications (1)

Publication Number Publication Date
AR046601A1 true AR046601A1 (es) 2005-12-14

Family

ID=34885905

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040103865A AR046601A1 (es) 2003-10-22 2004-10-22 Uso de derivados 1- aminociclohexano para modificar la deposicion de peptidos ab fibrosos en amiloidopatias

Country Status (13)

Country Link
US (1) US20050113458A1 (es)
EP (1) EP1682109B1 (es)
JP (1) JP2007509165A (es)
CN (1) CN1870984A (es)
AR (1) AR046601A1 (es)
AT (1) ATE411015T1 (es)
AU (1) AU2004316119B2 (es)
CA (1) CA2540921A1 (es)
DE (1) DE602004017207D1 (es)
IL (1) IL174970A0 (es)
TW (1) TW200526194A (es)
WO (1) WO2005079779A1 (es)
ZA (1) ZA200603231B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
MX2007012374A (es) 2005-04-06 2008-02-22 Adamas Pharmaceuticals Inc Metodos y composiciones para el tratamiento de condiciones relacionadas con cns.
US20070141148A1 (en) * 2005-11-30 2007-06-21 Merz Pharma Gmbh & Co. Kgaa Neramexane MR matrix tablet
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
GB0623897D0 (en) * 2006-11-30 2007-01-10 Pliva Istrazivanje I Razvoj D Pharmaceutical composition of memantine
ATE554085T1 (de) 2006-11-30 2012-05-15 Probiodrug Ag Neue inhibitoren von glutaminylcyclase
EP2117540A1 (en) 2007-03-01 2009-11-18 Probiodrug AG New use of glutaminyl cyclase inhibitors
RU2326660C1 (ru) * 2007-03-14 2008-06-20 Закрытое акционерное общество "Биологические исследования и системы" Пероральный лекарственный препарат мемантин (варианты) и способ его получения (варианты)
JP5667440B2 (ja) 2007-04-18 2015-02-12 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体
US20090118376A1 (en) * 2007-11-02 2009-05-07 Ru-Band Lu Memantine Protects Inflammation-Related Degeneration of Dopamine Neurons Through Inhibition of Over-Activated Microglia and Release of Neurotrophic Factors from Astroglia
WO2009111611A2 (en) * 2008-03-05 2009-09-11 Proteotech Inc. Compounds, compositions and methods for the treatment of islet amyloid polypeptide (iapp) accumulation in diabetes
ES2341517B1 (es) * 2008-03-28 2011-01-25 Farmalider, S.A Utilizacion de un compuesto inhibidor de la activacion de la enzima erk 1/2 en el tratamiento de enfermedades neurodegenerativas.
SG178953A1 (en) 2009-09-11 2012-04-27 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase
US20110236917A1 (en) * 2009-11-17 2011-09-29 Power3 Medical Products, Inc. Diagnosis of Alzheimer's Disease
US9181233B2 (en) 2010-03-03 2015-11-10 Probiodrug Ag Inhibitors of glutaminyl cyclase
AU2011226074B2 (en) 2010-03-10 2015-01-22 Vivoryon Therapeutics N.V. Heterocyclic inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5)
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
EP2578212B1 (en) 2010-05-24 2016-07-06 Farmalider, S.A. Compound inhibiting activation of the enzyme erk1/2 for use in the treatment of neurogenerative illnesses
CA2818025A1 (en) 2010-11-15 2012-05-24 Agenebio, Inc. Pyridazine derivatives, compositions and methods for treating cognitive impairment
ES2570167T3 (es) 2011-03-16 2016-05-17 Probiodrug Ag Derivados de benzimidazol como inhibidores de glutaminil ciclasa
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
EP3083569B1 (en) 2013-12-20 2022-01-26 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
WO2016205739A1 (en) 2015-06-19 2016-12-22 Belew Mekonnen Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
WO2017223402A1 (en) 2016-06-23 2017-12-28 Corium International, Inc. Adhesive matrix with hydrophilic and hydrophobic domains and a therapeutic agent
MX2019001104A (es) 2016-07-27 2019-10-02 Corium Int Inc Sistemas de suministro transdermico de memantina.
KR102406536B1 (ko) 2016-07-27 2022-06-08 코리움, 인크. 도네페질 경피 전달 시스템
CN109789134A (zh) 2016-07-27 2019-05-21 考里安国际公司 与口服递送药代动力学生物等效的透皮递送系统
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
BR112019012821A2 (pt) 2016-12-19 2019-11-26 Agenebio Inc derivados de benzodiazepina, composições e métodos para o tratamento do comprometimento cognitivo
US11548893B2 (en) 2017-07-15 2023-01-10 Arisan Therapeutics Inc. Enantiomerically pure adamantane carboxamides for the treatment of filovirus infection
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa
US11173132B2 (en) 2017-12-20 2021-11-16 Corium, Inc. Transdermal adhesive composition comprising a volatile liquid therapeutic agent having low melting point
CN112601749B (zh) 2018-06-19 2024-03-26 艾吉因生物股份有限公司 用于治疗认知损害的苯并二氮杂环庚三烯衍生物，组合物和方法
WO2024039886A1 (en) 2022-08-19 2024-02-22 Agenebio, Inc. Benzazepine derivatives, compositions, and methods for treating cognitive impairment

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3691016A (en) * 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
NL7305644A (es) * 1972-04-20 1973-10-23
CA1023287A (en) * 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4195128A (en) * 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) * 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) * 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) * 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
DE2856393C2 (de) * 1978-12-27 1983-04-28 Merz + Co GmbH & Co, 6000 Frankfurt Arzneimittel zur Behandlung von Morbus Parkinson
US5366738A (en) * 1982-07-29 1994-11-22 Merck & Co., Inc. Controlled release drug dispersion delivery device
US4503030A (en) * 1983-06-06 1985-03-05 Alza Corporation Device for delivering drug to certain pH environments
US4615698A (en) * 1984-03-23 1986-10-07 Alza Corporation Total agent osmotic delivery system
US4737456A (en) * 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4666829A (en) * 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
US6024983A (en) * 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
US4849222A (en) * 1987-03-24 1989-07-18 The Procter & Gamble Company Mixtures for treating hypercholesterolemia
JP2670680B2 (ja) * 1988-02-24 1997-10-29 株式会社ビーエムジー 生理活性物質含有ポリ乳酸系微小球およびその製造法
ATE94384T1 (de) * 1989-04-14 1993-10-15 Merz & Co Gmbh & Co Verwendung von adamantan-derivaten zur praevention und behandlung der cerebralen ischaemie.
US5912410A (en) * 1990-06-15 1999-06-15 Scios Inc. Transgenic non-human mice displaying the amyloid-forming pathology of alzheimer's disease
US5614560A (en) * 1991-04-04 1997-03-25 Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
US5955317A (en) * 1993-01-25 1999-09-21 Takeda Chemical Industries, Ltd. Antibodies to β-amyloids or their derivatives and use thereof
TW593225B (en) * 1997-06-30 2004-06-21 Merz Pharma Gmbh & Co Kgaa 1-amino-alkylcyclohexane NMDA receptor antagonists
US6080778A (en) * 1998-03-23 2000-06-27 Children's Medical Center Corporation Methods for decreasing beta amyloid protein
GB0018272D0 (en) * 2000-07-25 2000-09-13 Vernalis Research Limited Chemical compounds IV
US20040102525A1 (en) * 2002-05-22 2004-05-27 Kozachuk Walter E. Compositions and methods of treating neurological disease and providing neuroprotection
US20040019118A1 (en) * 2002-07-19 2004-01-29 Khalid Iqbal NMDA receptor antagonists and their use in inhibiting abnormal hyperphosphorylation of microtubule associated protein tau
EP1556019A2 (en) * 2002-10-24 2005-07-27 Merz Pharma GmbH & Co. KGaA Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors

Also Published As

Publication number Publication date
ATE411015T1 (de) 2008-10-15
AU2004316119B2 (en) 2008-04-24
ZA200603231B (en) 2007-11-28
JP2007509165A (ja) 2007-04-12
WO2005079779A1 (en) 2005-09-01
CN1870984A (zh) 2006-11-29
EP1682109A1 (en) 2006-07-26
IL174970A0 (en) 2006-08-20
DE602004017207D1 (de) 2008-11-27
EP1682109B1 (en) 2008-10-15
CA2540921A1 (en) 2005-09-01
AU2004316119A1 (en) 2005-09-01
US20050113458A1 (en) 2005-05-26
TW200526194A (en) 2005-08-16

Similar Documents

Publication Publication Date Title
AR046601A1 (es) Uso de derivados 1- aminociclohexano para modificar la deposicion de peptidos ab fibrosos en amiloidopatias
Sprott et al. Pain treatment of fibromyalgia by acupuncture
Jessop et al. Autophagy deficiency in macrophages enhances NLRP3 inflammasome activity and chronic lung disease following silica exposure
Hoefert et al. Importance of microcracks in etiology of bisphosphonate-related osteonecrosis of the jaw: a possible pathogenetic model of symptomatic and non-symptomatic osteonecrosis of the jaw based on scanning electron microscopy findings
AR071732A1 (es) Metodos para tratar la enfermedad de alzheimer, reducir la disminucion del volumen cerebral y monitorear una poblacion de pacientes que experimentan tratamiento o profilaxis para una enfermedad, uso de una medida de numero de copia apoe4, forma humanizada de un anticuerpo y acido nucleico aislado.
WO2009137217A3 (en) Therapeutic replenishment and enrichment of ocular surface lubrication
AR111572A2 (es) Formas farmacéuticas que contienen vardenafilo
PE20040134A1 (es) Forma de dosificacion de una vez al dia de pramipexol
BR0316050A (pt) Métodos de tratar, controlar ou prevenir um câncer especìfico e doença associada com angiogênese indesejada e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo e com terapia de radiação, terapia hormonal, terapia biológica, ou imunoterapia em um paciente sofrendo de um câncer especìfico, composição farmacêutica e kit
AR070025A1 (es) Uso de derivados de 1-amino-alquilciclohexano para el tratamiento del tinnitus coclear y composicion farmaceutica
ATE535257T1 (de) Ophthalmologische formulierung mit methylsulfonylmethan und ciprofloxacin
MXPA05012155A (es) Metodos y composiciones que utilizan compuestos inmunomoduladores para el tratamiento y manejo de canceres y otras enfermedades.
BRPI0416752A (pt) composição farmacêutica, uso de um ou mais compostos, método para a prevenção ou tratamento de distúrbios, compostos, e, processo para a preparação de uma composição farmacêutica
BRPI0412909A (pt) uso de rnai inibindo atividade de parp para a fabricação de um medicamento para o tratamento de cáncer
BRPI0607168A2 (pt) terapia de combinação parenteral, composição farmacêutica, processo para preparar uma composição farmacêutica e método de tratamento
EP2331095A4 (en) CYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF
AR069244A1 (es) Metodos para administrar n-( 5- ter- butil- isoxixasol-3-il) -n'- (4(7-(2- morfolin-4-il- etoxi) imidazo (2,1-b) (1,3) benzotiazol -2-il) fenil) urea para tratar una enfermedad proliferante y composicion farmaceutica
MA32458B1 (fr) Combinaison d'un antagoniste de c-met et d'un compose aminoheteroaryle pour le traitement d'un cancer
BRPI0519656A2 (pt) terapia de combinaÇço compreendendo telmisartan e hidroclorotiazida
AR095338A1 (es) Método de tratamiento no tóxico para la abstinencia de drogas
Feng et al. Cynaroside protects the blue light-induced retinal degeneration through alleviating apoptosis and inducing autophagy in vitro and in vivo
BRPI0418742A (pt) métodos de tratamento, prevenção ou controle de uma sìndrome mielodisplásica, de redução ou evitação de um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de um sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária única, e, kit
AU2009246603A8 (en) Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction
JP2002508321A (ja) 抗腫瘍薬としての使用のための多触媒性プロテアーゼ阻害剤
UY32600A (es) Formulación en lípidos de un promotor de la apoptosis

Legal Events

Date Code Title Description
FA Abandonment or withdrawal